Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303056 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 590
- Enrollment target
NCT00303056 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 590 participants.
The verdict
NCT00303056, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 590 participants
- Enrollment target
Study Summary
The primary objective is to compare the overall treatment effect on pain relief between icatibant and placebo. The secondary objectives are to assess the efficacy of icatibant in term of onset, extent and duration of pain relief relative to triamcinolone, to evaluate the safety of icatibant, to evaluate overall conditions of daily life after treatment with icatibant, to assess systemic exposure of icatibant following intra-articular injection.
Interventions
- DRUG HOE140 Icatibant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303056
The ClinicalTrials.gov registry entry for NCT00303056 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 590 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HOE140 Icatibant is the first listed.
NCT00303056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303056 about?
NCT00303056 is a clinical study titled "Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis". The primary objective is to compare the overall treatment effect on pain relief between icatibant and placebo. The secondary objectives are to assess the efficacy of icatibant in term of onset, extent and duration of pain relief relative to triamcinolone, to evaluate the safety of icatibant, to eval...
What is the current status of trial NCT00303056?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 590 participants. The study started on 2006-02. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00303056?
The interventions under investigation include: HOE140 Icatibant (DRUG).
Who is sponsoring clinical trial NCT00303056?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.